Health Care [ 4/12 ] | Life Sciences Tools & Services [ 21/72 ]
NYSE | Common Stock
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.
The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.
The company has a collaboration with argenx SE.
The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017.
IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 22, 24 | 2.64 Increased by +8.64% | 2.57 Increased by +2.72% |
| May 2, 24 | 2.54 Increased by +3.67% | 2.48 Increased by +2.42% |
| Feb 14, 24 | 2.84 Increased by +2.16% | 2.82 Increased by +0.71% |
| Nov 1, 23 | 2.49 Increased by +0.40% | 2.44 Increased by +2.05% |
| Aug 1, 23 | 2.43 Decreased by -0.41% | 2.37 Increased by +2.53% |
| Apr 27, 23 | 2.45 Decreased by -0.81% | 2.41 Increased by +1.66% |
| Feb 10, 23 | 2.78 Increased by +9.02% | 2.76 Increased by +0.72% |
| Oct 26, 22 | 2.48 Increased by +14.29% | 2.38 Increased by +4.20% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 3.74 B Increased by +4.88% | 303.00 M Increased by +7.07% | Increased by +8.11% Increased by +2.08% |
| Jun 30, 23 | 3.73 B Increased by +5.28% | 297.00 M Increased by +16.02% | Increased by +7.97% Increased by +10.20% |
| Mar 31, 23 | 3.65 B Increased by +2.35% | 289.00 M Decreased by -11.08% | Increased by +7.91% Decreased by -13.12% |
| Dec 31, 22 | 3.74 B Increased by +2.83% | 227.00 M Decreased by -28.62% | Increased by +6.07% Decreased by -30.58% |
| Sep 30, 22 | 3.56 B Increased by +5.04% | 283.00 M Increased by +8.43% | Increased by +7.94% Increased by +3.22% |
| Jun 30, 22 | 3.54 B Increased by +3.00% | 256.00 M Increased by +46.29% | Increased by +7.23% Increased by +42.03% |
| Mar 31, 22 | 3.57 B Increased by +4.66% | 325.00 M Increased by +53.30% | Increased by +9.11% Increased by +46.47% |
| Dec 31, 21 | 3.64 B Increased by +10.25% | 318.00 M Increased by +167.23% | Increased by +8.75% Increased by +142.39% |